Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. AKBA

Healthcare  —  Drug Manufacturers Specialty & Generic
0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue 236.20 160.18 194.62 292.48 211.65 294.64 335.00 207.74 181.23 1.54
Revenue Growth 47.46% (17.70%) (33.46%) 38.19% (28.17%) (12.05%) 61.26% 14.63% 11,706.32% (99.15%)
Cost of Revenue 39.46 63.18 74.15 85.57 150.67 182.05 145.34 7.77 0.62 —
Gross Profit 196.73 97.00 120.47 206.92 60.98 112.59 189.67 199.97 181.23 1.54
R&D Expenses 62.36 37.65 63.08 129.99 147.85 218.49 322.97 291.01 230.89 115.79
SG&A Expenses 107.48 106.55 100.23 138.60 174.14 154.10 149.46 87.06 27.01 22.21
Operating Income 23.50 (50.47) (46.26) (80.78) (264.50) (377.83) (286.29) (178.16) (76.67) (136.46)
Non-operating Income/Expense (27.22) (18.94) (5.67) (13.45) (17.52) (7.01) 0.00 6.24 3.00 0.71
Non-operating Interest Expenses 24.18 18.19 6.03 15.69 19.94 8.87 (0.79) 6.15 2.80 0.90
EBT (3.72) (69.41) (51.92) (94.23) (282.02) (384.84) (286.29) (171.93) (73.67) (135.75)
Income Tax Provision 1.62 — — — — — (6.63) (28.34) — —
Income after Tax (5.34) (69.41) (51.92) (94.23) (282.02) (384.84) (279.66) (143.59) (73.67) (135.75)
Net Income Common (5.34) (69.41) (51.92) (94.23) (282.02) (384.84) (279.66) (143.59) (73.67) (135.75)
EPS (Basic) (0.02) (0.33) (0.28) (0.51) (1.70) (2.77) (2.36) (2.47) (1.77) (3.60)
EPS (Diluted) (0.02) (0.33) (0.28) (0.51) (1.70) (2.77) (2.36) (2.47) (1.77) (3.60)
Shares (Basic, Weighted) 257.16 210.95 187.47 182.78 165.95 138.46 118.40 58.04 43.50 37.72
Shares (Diluted, Weighted) 257.16 210.95 187.47 182.78 165.95 138.46 118.40 58.04 43.50 37.72
Gross Margin 83.29% 60.56% 61.90% 70.74% 28.81% 38.21% 56.62% 96.26% 100.00% 100.00%
EBIT Margin 9.95% (31.51%) (23.77%) (27.62%) (124.97%) (128.23%) (85.46%) (85.76%) (42.31%) (8,889.90%)
EBT margin (1.58%) (43.33%) (26.68%) (32.22%) (133.25%) (130.61%) (85.46%) (82.76%) (40.65%) (8,843.45%)
Net Profit Margin (2.26%) (43.33%) (26.68%) (32.22%) (133.25%) (130.61%) (83.48%) (69.12%) (40.65%) (8,843.45%)
Free Cash Flow Margin 28.74% (25.40%) (12.02%) (25.05%) (119.55%) (37.57%) (78.83%) (47.70%) (31.88%) 3,598.96%
EBITDA 24.77 (12.97) (8.63) (43.08) (226.55) (228.76) (248.46) (176.97) (75.45) (135.67)
EBIT 23.50 (50.47) (46.26) (80.78) (264.50) (377.83) (286.29) (178.16) (76.67) (136.46)
Income from Continuous Operations (5.34) (69.41) (51.92) (94.23) (282.02) (384.84) (279.66) (143.59) (73.67) (135.75)
Consolidated Net Income/Loss (5.34) (69.41) (51.92) (94.23) (282.02) (384.84) (279.66) (143.59) (73.67) (135.75)
EPS (Basic, from Continuous Ops) (0.02) (0.33) (0.28) (0.52) (1.70) (2.78) (2.36) (2.47) (1.69) (3.60)
EPS (Basic, Consolidated) (0.02) (0.33) (0.28) (0.52) (1.70) (2.78) (2.36) (2.47) (1.69) (3.60)
EPS (Diluted, from Cont. Ops) (0.02) (0.33) (0.28) (0.52) (1.70) (2.78) (2.36) (2.47) (1.69) (3.60)
Shares (Diluted, Average) 257.16 210.95 187.47 182.78 165.95 138.46 118.40 58.04 43.50 37.72
EPS (Diluted, Consolidated) (0.02) (0.33) (0.28) (0.52) (1.70) (2.78) (2.36) (2.47) (1.69) (3.60)
EBITDA Margin 10.49% (8.10%) (4.43%) (14.73%) (107.04%) (77.64%) (74.17%) (85.19%) (41.63%) (8,838.44%)
Operating Cash Flow Margin 28.79% (25.38%) (12.02%) (25.01%) (119.52%) (37.46%) (76.85%) (46.93%) (30.99%) 3,772.38%

Fold the line items

In millions of $ except per-share values · columns are period end dates